A new study presented at the European Association of Nuclear Medicine (EANM'25) indicates that GLP-1 receptor agonists, used primarily for diabetes and obesity management, can significantly alter the interpretation of FDG-PET-CT scans, potentially leading to misdiagnoses in cancer detection. The study noted an increased uptake of FDG in muscles, heart, and fat tissue among patients using these medications, which could be mistaken for malignant disease. While a 700% increase in GLP-1 usage among U.S. adults from 2019 to 2023 was observed, researchers emphasized the need for better documentation of patients' medication histories during scans, rather than altering patient preparation. Current guidelines in Australia have been updated, yet the UK is lacking. The researchers plan to expand their data collection to inform future international guidelines for reliable PET-CT interpretation.
Thu, 09 Oct 2025 17:45:03 GMT | Pharmacy Times